ACTH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
纯度评估以反相高效液相色谱为主，通过主峰面积百分比给出粗略结果，再配合电喷雾质谱核对分子量。氨基酸分析可验证组成比例，手性色谱或毛细管电泳用于检查残基构型。常见杂质包括缺失序列的短肽、氧化产物与二聚体。由于多数市售品不附带完整检验报告，独立第三方检测常被用来核实标称值。
从分子层面看，Semax 是线性七肽，没有二硫键、糖基或脂链修饰，N 端为游离氨基，C 端为游离羧基。分子含组氨酸与谷氨酸侧链，因此在水和甲醇等极性溶剂中溶解良好，在非极性溶剂中溶解有限。计算分子量约为 814 Da，与其质子化离子的质荷比吻合，可用于质谱确认。
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.
At the beginning of the 3rd century BCE the cities of southern Italy, which had been allies of the Samnites, were still independent, but inevitably came into conflict as a result of Rome's expansion as their expansion in central and northern Italy was not sufficient to provide arable lands they needed.
=== Television === Mogo appears in the Batman: The Brave and the Bold episode "The Eyes of Despero!". Mogo appears in Green Lantern: The Animated Series, voiced by Kevin Michael Richardson. Mogo appears in the Mad segment "Does Someone Have to GOa?", voiced by Fred Tatasciore. Mogo and his debut story are referenced in the DC Universe series Lanterns, with Hal Jordan's vault being activated with the voice password "Mogo doesn't socialize".
Vitrification (from Latin vitrum 'glass', via French vitrifier) is the full or partial transformation of a substance into glass. In the production of ceramics, vitrification is responsible for their impermeability to water. The most common applications are in the making of pottery, glass, and some types of food, but there are many others, such as the vitrification of an antifreeze-like liquid in cryopreservation. Vitrification is also used in the disposal and long-term storage of radioactive waste, in which the waste is immobilized within a hardened glass material considered more stable for containment. It has also been proposed, though disputed, that the extreme heat of the eruption of Mount Vesuvius in 79 AD vitrified the brain of at least one victim.
=== Sahrawi Arab Democratic Republic === The Castillo Administration recognized the Sahrawi Arab Democratic Republic, a partially-recognized state claimed by Morocco. Although the recognition came without forewarning, officially it was due to Castillo's push for a foreign policy based on self-determination and non-intervention. The Congressional opposition has opposed the recognition of the SADR, claiming that it creates geopolitical instability and risks Peru's relations with the Middle East.
Sources: en.wikipedia.org
=== Narcotic analgesics === Narcotic analgesics tend to be opioids. They bind to opioid receptors which are G protein-coupled receptors distributed in brain, spinal cord, digestive tract, peripheral neurons.
== Mechanism of action == Copanlisib is an inhibitor of phosphatidylinositol-3-kinase (PI3K) with inhibitory activity predominantly against PI3K-α and PI3K-δ isoforms expressed in malignant B-cells. It has been shown to induce tumor cell death by apoptosis and inhibition of proliferation of primary malignant B cell lines.
== Antagonists == Becampanel CNQX Dasolampanel DNQX Fanapanel (MPQX) Kaitocephalin Kynurenic acid – endogenous ligand L-theanine NBQX 3,5-Dibromo-L-phenylalanine, a naturally occurring halogenated derivative of L-phenylalanine Perampanel Selurampanel Tezampanel Zonampanel
On May 14, 1913, New York Governor William Sulzer approved a charter for the foundation with Junior becoming the first president. With its large-scale endowment, a large part of Senior's fortune was insulated from inheritance taxes. The first secretary of the foundation was Jerome Davis Greene, the former secretary of Harvard University, who wrote a "memorandum on principles and policies" for an early meeting of the trustees that established a rough framework for the foundation's work. It was initially located within the family office at Standard Oil's headquarters at 26 Broadway, later (in 1933) shifting to the GE Building (then RCA), along with the newly named family office, Room 5600, at Rockefeller Center; later it moved to the Time-Life Building in the center, before shifting to its current Fifth Avenue address. In 1914, the trustees set up a new Department of Industrial Relations, inviting William Lyon Mackenzie King to head it. He became a close and key advisor to Junior through the Ludlow Massacre, turning around his attitude to unions; however the foundation's involvement in IR was criticized for advancing the family's business interests. The foundation henceforth confined itself to funding responsible organizations involved in this and other controversial fields, which were beyond the control of the foundation itself.
=== Cyclic mechanical reinforcement === Most catch bonds were demonstrated using force-clamp force spectroscopy where upon initial ramping, a constant force is loaded on the bond to observe how long the bond lasts, i.e., measuring the bond lifetime at a constant force. Catch bonds are revealed when the mean bond lifetime (reciprocally related to the rate of bond dissociation) increases with the clamped force. Zhu and colleagues demonstrated that bond lifetime measured at the force-clamp phase could be substantially prolonged if the initial ramping included two forms of pre-conditioning: 1) loading the bond by ramping the force to a high level (peak force) before clamping the force at a low level for lifetime measurement, and 2) loading and unloading the bond repeatedly by multiple force cycles before clamping the force at a peak value for lifetime measurement. This new bond type, termed cyclic mechanical reinforcement (CMR), is distinct from catch bond, but it nevertheless resembles catch bond in that the bond lifetime increases with the peak force and with the number of cycles used to pre-condition the bond. CMR has been observed for interactions between integrin alpha 5 beta 1 and fibronectin and between G-actin and G-actin or F-actin.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.